

Notice of an extraordinary general meeting of Chordate Medical Holding AB (publ)

The shareholders of Chordate Medical Holding AB (publ) in liquidation, 556962-6319, (the "Company") are hereby invited to attend an extraordinary general meeting on Friday 24 April 2026, at 10:00 am at CMS Wistrand Advokatbyrå, Jakobsbergsgatan 24, Stockholm.

Registration and notification

Shareholders wishing to attend the general meeting shall

- be listed in the register of shareholders maintained by Euroclear Sweden AB as of Thursday 16 April 2026,
- *and* no later than Monday 20 April 2026, notify the company of their intention to attend the meeting by post to Chordate Medical Holding AB (publ), c/o CMS Wistrand Advokatbyrå, Box 7543, 103 93 Stockholm (please mark the envelope "EGM Chordate") or by email to chordate@cms-wistrand.com.

For shareholders whose shares are held in a nominee account through a bank or other nominee, the following applies in order to be entitled to attend the meeting. In addition to registering for the meeting, such shareholders must re-register their shares in their own name so that the shareholder is registered in the share register maintained by Euroclear Sweden AB as at the record date of 16 April 2026. Such re-registration may be temporary (so-called voting rights registration). Shareholders wishing to register their shares in their own name must, in accordance with the procedures of the relevant custodian, request that the custodian carry out such registration. Voting rights registration requested by shareholders in such a manner that the registration has been completed by the custodian no later than 20 April 2026 will be taken into account when compiling the share register.

Power of attorney

If a shareholder wishes to attend the general meeting by proxy, a written and dated power of attorney signed by the shareholder in original must be brought to the meeting or, to facilitate registration, sent by post in good time to Chordate Medical Holding AB (publ), c/o CMS Wistrand Advokatbyrå, Box 7543, 103 93 Stockholm. A proxy form is available on the company's website www.chordate.com. If the shareholder is a legal entity, a certificate of registration or other document of authority must be attached to the form.

Agenda of the general meeting

1. Opening of the general meeting
2. Election of the chairman of the general meeting
3. Preparation and approval of the voting register
4. Election of one or two persons to verify the minutes
5. Determination of whether the general meeting has been duly convened
6. Approval of the agenda
7. Resolution on the transfer of shares in the subsidiary Chordate Medical AB
8. Closing of the meeting

Proposed resolution

Item 7 – Resolution regarding the transfer of shares in the subsidiary Chordate Medical AB

The liquidator proposes that the general meeting approve the Company's transfer of all shares in the wholly-owned subsidiary Chordate Medical AB (the "Subsidiary") on the following grounds and with the following main content.

1. For just over a year, the Company has engaged an external international consultancy firm to attempt to find a buyer for all the shares in the Subsidiary. Unfortunately, there has been no interest from third parties in acquiring the Subsidiary. Following the Company's placement in liquidation, the liquidator has sought to identify potential interested parties within the industry for the acquisition of the Subsidiary. This has also proved unsuccessful. However, the liquidator has identified a purchaser, Jilkén Invest AB (the "Purchaser"), for the Subsidiary, which, in summary, will acquire the shares on the following terms.
2. A share transfer agreement has been entered into but is subject to the approval of the general meeting. The initial provisional purchase price is SEK 1,635,878 and is based on the Subsidiary's balance sheet as of 25 March 2026, with the possibility of an additional purchase price during 2026.
3. The Company and the Purchaser agree that the Purchaser shall assist in ensuring that the Subsidiary's assets are, where possible, sold to a third party during 2026. For this purpose, the Purchaser shall ensure that the Subsidiary engages a consultancy firm to manage the sale. Such consultancy firm shall be approved by the Company. Upon the sale of the Subsidiary's assets in 2026, the Purchaser shall pay an additional purchase price to the Company. The Company and the Purchaser also agree that the Purchaser shall pay an additional purchase price on a krona-for-krona basis for payments on outstanding trade receivables. If the Subsidiary has a positive cash balance in 2026 after deduction of liabilities, the surplus shall be paid as an additional purchase price.
4. Consultations shall take place between the Company, the Purchaser and the consultancy firm regarding the pricing of assets and whether assets are to be disposed of. If these parties cannot reach an agreement, the Company shall make the final decision on whether assets are to be disposed of and, if so, for what purchase price. The Company and the Purchaser agree to conduct ongoing reconciliations to determine the total purchase price.

Miscellaneous

If any shareholder so requests and the liquidator considers that this can be done without material detriment to the Company, the liquidator shall provide information regarding circumstances that may affect the assessment of an item on the agenda.

The Liquidator's full proposal for a resolution in accordance with item 7 will be available on the Company's website, www.chordate.com, no later than two weeks prior to the general

meeting. Copies of this document will be sent to shareholders who request them and provide their email address.

For information on the processing of personal data, please refer to the privacy policy available at the following link: [https://www.euroclear.com/dam/ESw/Legal/ Privacy-notice-bolagsstammor-engelska.pdf](https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf)

Chordate Medical Holding AB (publ) in liquidation
The Liquidator